This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101188158.
PRIM-TECH3R
Preclinical in vitro Models for the Replacement, Reduction and Refinement of Mouse Models in Preclinical Studies
Photo credit: R. Bengaiev
Project Period:
1 April 2025 – 31 March 2028
Total Cost:
€9M
Grant Agreement:
101188158
Coordinated by
INFRAFRONTIER ERIC
Project Description
The use of mouse models in biomedical research has been pivotal in understanding human diseases due to their genetic and physiological similarities to humans. However, concerns on ethics and translatability have prompted a shift towards alternative methods such as complex in vitro models (CIVMs). PRIM-TECH3R addresses this shift by leveraging advanced technologies to develop reliable mouse and human CIVMs for preclinical studies, aiming to reduce and refine the use of animal models. Through standardised protocols and robust validation procedures, the project will create state-of-the-art in vitro models from mouse disease models, complementing existing in vivo models. This initiative aligns with EU policy objectives and societal demands to address phasing out of animal testing in biomedical research. The project will establish a comprehensive repository of preclinical resources, ensure open access, and foster collaboration between research infrastructures and the biomedical industry. Training programmes will equip personnel with the necessary skills to provide CIVMs to the research community. By achieving these objectives, PRIM-TECH3R aims to advance the state-of-the-art in research infrastructures, facilitate industrial exploitation, and contribute to transformative changes in biomedical research practices.
PRIM-TECH3R’s major outcome
PRIM-TECH3R Consortium
10 European countries
18 institutions
3 Research Infrastructures
Click on the pins to learn more about our project partners!
Work Packages
WP | Title | Lead Partner |
WP1 | Standardised isolation of relevant mouse cells and pilot mouse biobanking | UKRI |
WP2 | Development, characterisation, and drug testing studies for Complex in vitro models | CIPHE |
WP3 | In vivo validation of CIVMs and development of cellular disease models | ICS |
WP4 | PRIM-TECH3R In Vitro Resource, data management and commercial exploitation | INFRAFRONTIER |
WP5 | Communication, Dissemination, Training, and Industry Engagement | INFRAFRONTIER |
WP6 | Project Management and Coordination | INFRAFRONTIER |
WP7 | Ethics requirements | INFRAFRONTIER |
INFRAPLUS and PRIM-TECH3R will be funded
